Skip to main content

01.12.2018 | Research article | Ausgabe 1/2018 Open Access

BMC Cancer 1/2018

Variations of circulating cardiac biomarkers during and after anthracycline-containing chemotherapy in breast cancer patients

BMC Cancer > Ausgabe 1/2018
Pierre Frères, Nassim Bouznad, Laurence Servais, Claire Josse, Stéphane Wenric, Aurélie Poncin, Jérôme Thiry, Marie Moonen, Cécile Oury, Patrizio Lancellotti, Vincent Bours, Guy Jerusalem
Wichtige Hinweise

Electronic supplementary material

The online version of this article (https://​doi.​org/​10.​1186/​s12885-018-4015-4) contains supplementary material, which is available to authorized users.



Over time, the chance of cure after the diagnosis of breast cancer has been increasing, as a consequence of earlier diagnosis, improved diagnostic procedures and more effective treatment options. However, oncologists are concerned by the risk of long term treatment side effects, including congestive heart failure (CHF).


In this study, we evaluated innovative circulating cardiac biomarkers during and after anthracycline-based neoadjuvant chemotherapy (NAC) in breast cancer patients. Levels of cardiac-specific troponins T (cTnT), N-terminal natriuretic peptides (NT-proBNP), soluble ST2 (sST2) and 10 circulating microRNAs (miRNAs) were measured.


Under chemotherapy, we observed an elevation of cTnT and NT-proBNP levels, but also the upregulation of sST2 and of 4 CHF-related miRNAs (miR-126-3p, miR-199a-3p, miR-423-5p, miR-34a-5p). The elevations of cTnT, NT-proBNP, sST2 and CHF-related miRNAs were poorly correlated, suggesting that these molecules could provide different information.


Circulating miRNA and sST2 are potential biomarkers of the chemotherapy-related cardiac dysfunction (CRCD). Nevertheless, further studies and long-term follow-up are needed in order to evaluate if these new markers may help to predict CRCD and to identify the patients at risk to later develop CHF.
Additional file 1: Statistical analyses. (A) Correlations Spearman tests between the fold change of cTnT, NT-proBNP, sST2, miR-126-3p, miR-199a-3p, miR-423-5p and miR-34a-5p at different time point of the neoadjuvant chemotherapy in 45 breast cancer patients. (B) Comparison between the increase of the markers at the end of the chemotherapy (NA1 vs. D8 and NA1 vs. 3 M) in patients treated (n = 17) or not (n = 28) with HER2 targeted therapy, using Mann-Whitney tests. (XLSX 50 kb)
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2018

BMC Cancer 1/2018 Zur Ausgabe


Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.